Lung Cancer Resection - Pathology Staging and Margins

Key Points

• Use the current CAP lung resection protocol for essential reporting elements.
• Report a specific histologic type rather than NSCLC not otherwise specified whenever morphology and ancillary testing permit.
• Tumor size, invasion, separate nodules, pleural involvement, margins, and lymph nodes determine pathologic stage.
• Invasive size rules can differ from total tumor size in selected adenocarcinomas.
• Margin positivity must be distinguished from a close but negative margin.
• Lymph-node station and involvement are central staging data.
• Neoadjuvant specimens require assessment of treatment effect and residual viable tumor.
• Preserve tissue for predictive biomarker testing.
• Spread through air spaces has prognostic significance but should not be improvised into TNM staging.
• Unexpected staging or margin findings should be communicated to the multidisciplinary team.

Algorithm

1. Orient the specimen and identify bronchial, vascular, parenchymal, pleural, and other relevant margins.
2. Correlate gross tumor location with imaging and operative information.
3. Measure total tumor and invasive components according to current protocol.
4. Sample the tumor to document histology, invasion, pleural relationship, and treatment effect when present.
5. Examine and report all submitted lymph nodes by station/designation.
6. Determine margin status and distance where protocol or clinical context requires it.
7. Assign histologic type and grade using current classification.
8. Assign pathologic TNM using the current CAP/AJCC framework.
9. Reserve representative tumor for PD-L1 and molecular testing when indicated.
10. Release a synoptic report containing all required core and conditional data elements.

Clinical Synopsis & Reasoning

A lung resection specimen must answer questions that cannot be resolved by biopsy alone. The pathologist confirms the histologic type according to current WHO classification, measures tumor size using staging-specific rules, evaluates invasion of pleura and adjacent structures, assesses bronchial and vascular relationships, examines margins, and reports lymph nodes by submitted station or designation. These elements determine pathologic stage and guide adjuvant treatment, prognosis, and surveillance.

Tumor size is not always simply the largest gross dimension. In nonmucinous adenocarcinoma with a lepidic component, invasive size can determine T classification under current staging rules, while the total size remains clinically descriptive. Visceral pleural invasion can upstage a tumor and may require elastic stains when routine histology is equivocal. Separate tumor nodules, invasion of chest wall or mediastinal structures, and involvement of the main bronchus or carina are handled by defined TNM criteria. The current CAP protocol should be used rather than relying on memory because staging definitions evolve.

Margins require precise identification. Bronchial, vascular, parenchymal, chest-wall, and other margins are reported as involved or uninvolved with the relevant invasive or in-situ component. A close but negative margin is not the same as a positive margin. In wedge or segmental resections, the parenchymal margin distance can be particularly important for multidisciplinary planning. Lymph nodes should be counted and assigned to stations as submitted; fragmented nodes can complicate exact counts, so gross handling and surgeon-pathologist communication matter.

Histologic features influence prognosis and therapy. Adenocarcinoma patterns, squamous differentiation, lymphovascular invasion, spread through air spaces, pleural invasion, and high-grade components may be reported according to protocol and institutional practice. Spread through air spaces is prognostically important but should not be treated as a staging category unless the current protocol specifically incorporates it. For neuroendocrine tumors, mitotic activity, necrosis, and classification require tumor-specific criteria.

After neoadjuvant therapy, the specimen also documents treatment effect, residual viable tumor, tumor bed size, nodal response, and other protocol-defined elements. Tissue stewardship is essential because molecular testing and PD-L1 assessment may be required for systemic-therapy decisions. Excessive block exhaustion on nonessential stains can compromise downstream predictive testing.

Treatment Strategy & Disposition

Pathology findings are integrated in a multidisciplinary plan. Completely resected early-stage tumors may require surveillance or adjuvant therapy depending on stage, histology, molecular features, and current oncology guidelines. Positive margins can prompt consideration of re-resection, radiation, or systemic therapy depending on location and stage. Nodal metastasis changes pathologic stage and can materially alter adjuvant recommendations.

Biomarker testing should follow tumor type, stage, and current systemic-treatment guidelines. For non-small cell lung cancer, actionable driver testing and PD-L1 assessment are increasingly relevant not only in metastatic disease but in selected resected disease because adjuvant targeted and immune therapies have expanded. The pathology laboratory must triage tissue to maintain adequate tumor content for validated molecular platforms.

If the specimen reveals an unexpected metastatic tumor rather than a primary lung cancer, immunohistochemistry and clinical correlation should identify the likely origin without exhausting tissue. Poorly differentiated tumors require a focused panel rather than indiscriminate stains. Pathology should also communicate unexpected findings such as positive margins, unsuspected nodal disease, or a major staging discrepancy promptly when they will change near-term management.

Epidemiology / Risk Factors

• Lung cancer remains a leading cause of cancer mortality worldwide.
• Most resected lung cancers are non-small cell carcinomas, with adenocarcinoma the most common histologic type in many populations.
• Pathologic staging is available only when sufficient primary tumor and nodal tissue has been surgically sampled.
• Increasing use of neoadjuvant chemoimmunotherapy makes treatment-response assessment an expanding pathology responsibility.
• Molecularly targeted adjuvant therapy has increased the importance of tissue stewardship in resection specimens.

Investigations

Report Essentials

Pharmacology

Prognosis / Complications

• Pathologic stage is one of the strongest prognostic factors after lung cancer resection.
• Negative margins and absence of nodal metastasis generally predict better local and disease-free outcomes.
• Major pathologic response after neoadjuvant therapy can carry prognostic information, but its use must follow current definitions.
• Certain molecular alterations have strong predictive significance because effective targeted therapies are available.
• Recurrence risk remains meaningful even after complete early-stage resection, supporting guideline-based surveillance.

Patient Education / Counseling

• Explain that the final surgical pathology report provides more staging information than the original biopsy because the entire tumor, margins, and lymph nodes can be examined.
• Patients may need to wait for molecular or PD-L1 addenda after the main diagnosis because these tests require additional processing.
• Clarify that a 'close' margin is not necessarily a positive margin and that treatment decisions depend on the exact site and stage.
• Discuss the role of nodal findings in adjuvant treatment decisions.
• Encourage patients to keep the final pathology and molecular reports because they can guide future therapy if disease recurs.

Notes

CAP's current cancer protocols are living documents that incorporate contemporary WHO classification and AJCC staging. The laboratory should use the current protocol version in force rather than hard-coding staging rules into local prose that is not regularly updated. CAP's 2026 lung cancer quality measure specifically emphasizes reporting pT, pN, and a specific NSCLC histologic type.

Pathology and molecular laboratories should coordinate tissue triage before blocks are exhausted. A single well-chosen block with adequate viable tumor and minimal necrosis can support multiple predictive assays better than repeated small unstaged tests.

The report should be readable by surgeons, oncologists, radiation oncologists, and future clinicians. A synoptic format improves completeness, while a concise comment can resolve unusual multifocality, treatment effect, or staging questions that cannot be conveyed by checkboxes alone.

References

1. College of American Pathologists Current Cancer Protocols — Link
2. CAP Lung Cancer Resection Protocol — Link